Bioventus (BVS) reported Q4 non-GAAP earnings Tuesday of $0.15 per share, up from $0.07 a year earlier.
Three analysts surveyed by FactSet expected $0.08.
Revenue for the quarter ended Dec. 31 was $153.6 million, up from $135.4 million a year earlier.
Three analysts surveyed by FactSet expected $145.2 million.
Bioventus said it expects 2025 non-GAAP EPS of $0.64 to $0.68. Three analysts surveyed by FactSet expect $0.55.
Bioventus also said it expects 2025 net sales of $560 million to $570 million. Three analysts surveyed by FactSet expect $554.6 million.
The company's shares were up more than 26% in recent Tuesday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。